Pre‐existing, treatment‐specific resistance‐associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct‐acting antivirals.

MLA

Sølund, Christina, et al. “Pre‐existing, Treatment‐specific Resistance‐associated Substitutions in Hepatitis C Virus Genotype 1 and 3 and Viral RNA Titers during Treatment with Direct‐acting Antivirals.” APMIS, vol. 131, no. 8, Aug. 2023, pp. 426–33. EBSCOhost, https://doi.org/10.1111/apm.13335.

APA

Sølund, C., Pedersen, M. S., Fahnøe, U., Filskov, J., Jenssen, H., Weis, N., Schønning, K., & Bukh, J. (2023). Pre‐existing, treatment‐specific resistance‐associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct‐acting antivirals. APMIS, 131(8), 426–433. https://doi.org/10.1111/apm.13335

Chicago

Sølund, Christina, Martin S. Pedersen, Ulrik Fahnøe, Jonathan Filskov, Håvard Jenssen, Nina Weis, Kristian Schønning, and Jens Bukh. 2023. “Pre‐existing, Treatment‐specific Resistance‐associated Substitutions in Hepatitis C Virus Genotype 1 and 3 and Viral RNA Titers during Treatment with Direct‐acting Antivirals.” APMIS 131 (8): 426–33. doi:10.1111/apm.13335.